Sanofi - AGM 30 April 2019
ITEM 8: In line with the modified AFEP/MEDEF corporate governance code as revised
in June 2018, the company proposes to add a CSR criterion to the annual bonus. We
regret that the company does not indicate which CSR indicator will be implemented and
whether it will be quantifiable or not. However, the 2019 remuneration policy is better
than the previous one, therefore we support item 8.
ITEM 10: the company’s disclosure improved compared to last year as now it disclosed
achievement rates for each of the financial criteria. However, its transparency remains
below French and European standards (for example, Novartis, one of Sanofi’s European
competitors, disclosed targets of each annual bonus criterion and achievement rates). An
improved disclosure would allow for a better understanding of amounts granted (indeed,
the 2018 bonus amounting to €1,855,800 does not seem to be sufficiently justified).
We note that Olivier Brandicourt (CEO, 63) and Serge Weinberg (Chairman, 68) will
reach the statutory age limits (respectively 65 and 70) in 2021. The company's
transparency on its succession planning in the annual report is quite appreciated.
Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
- Proxy reports
- Definition and monitoring of client customized voting guidelines
- Corporate Governance Data and Rating
- Thematic research
- Engagement support
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.